Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2021-03-22 Capital/Financing Update
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
Aura Biosciences announces oversubscribed $80 million financing
Capital/Financing Update Classification · 1% confidence The document is an announcement by Arix Bioscience plc regarding its portfolio company, Aura Biosciences, closing an oversubscribed $80 million financing round. This event directly relates to fundraising, capital structure changes, and investment activity within the company's portfolio. This fits the definition of 'Capital/Financing Update' (CAP). Although it contains the full text of Aura's announcement, the primary purpose of the Arix filing is to report this financing event, not to release Arix's own periodic financial results (ER/IR) or present a general investor deck (IP). It is a specific announcement about capital raising.
2021-03-22 English
Share buyback programme of up to £25 million
Transaction in Own Shares Classification · 1% confidence The document explicitly announces the commencement of a 'Share buyback programme of up to £25 million'. It details the parameters of the repurchase, the agreement with Jefferies, and references regulatory compliance related to share repurchase. Crucially, the metadata table at the end includes 'Category Code: POS' and 'OAM Categories: 2.4. Acquisition or disposal of the issuer's own shares'. This directly maps to the definition for 'Transaction in Own Shares' (Code: POS). Although it is a regulatory announcement, the specific subject matter (share repurchase) makes POS a more precise classification than the general RNS.
2021-03-22 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a regulatory announcement disseminated via EQS Group, dated March 19, 2021. The core content is structured as 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership thresholds. Section 2 explicitly marks 'An acquisition or disposal of voting rights' as the reason for notification. Section 7 details the resulting shareholding percentage (2.9%) and the date the threshold was crossed (16 March 2021). This directly corresponds to the definition of a Major Shareholding Notification, which is classified as 'MRQ' in the provided schema.
2021-03-19 English
Share buyback programme of up to £25 million
Regulatory Filings Classification · 1% confidence The document is a short announcement (4093 characters) disseminated via a Regulatory Announcement service (EQS Group). The core content is the announcement of the Board's approval for a 'share buyback programme of up to £25 million'. This action directly relates to the company repurchasing its own shares. According to the definitions, 'Transaction in Own Shares (Code: POS)' covers 'Report of the company buying back or selling its own shares (share repurchase/issuance)'. Although it mentions further details will follow, the primary subject is the share repurchase decision itself, making POS the most accurate classification over a general RPA or RNS.
2021-03-15 English
Arix Bioscience plc Annual Report and Accounts for the year ended 31 December 2020
Annual Report Classification · 1% confidence The document is titled 'Annual report and accounts 2020' for Arix Bioscience plc. It contains comprehensive financial information, including a performance snapshot, business highlights, strategic report, corporate governance, and full financial statements. It is clearly the company's official annual report for the fiscal year 2020, fitting the definition of a 10-K (Annual Report). FY 2020
2021-03-10 English
Response to Activist Shareholder Acacia
Legal Proceedings Report Classification · 1% confidence The document is a short press release (3495 characters) issued by Arix Bioscience PLC titled "Response to Activist Shareholder Acacia". It addresses an open letter from a shareholder and mentions recent governance strengthening and progress highlighted in the Annual Results. Crucially, it does not contain the full text of the Annual Results or any other comprehensive report; instead, it links to them (e.g., "[Annual Results for the year ended 31 December 2020](...)"). According to Rule 2 (The "MENU VS MEAL" Rule), a short announcement that points to the existence of a report, rather than being the report itself, should be classified as a Report Publication Announcement (RPA). It is an announcement about company information/events, but RPA is the most specific fit for this type of linking release.
2021-03-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.